BR0009593A - Agente melhorador de resistência à insulina, agente hipoglicêmico, agente imunorregulador, inibidor de aldose redutase, inibidor de 5-lipoxigenase, supressor de produção de lipìdios peroxidados, ativador de ppar, antagonista de leucotrienos, promotor de formação hidroxiadipocelular ou antagonista de cálcio, agente preventivo e/ou terapêutico, derivados de ácido carboxìlico, medicamento, composição farmacêutica, e, uso de um composto - Google Patents
Agente melhorador de resistência à insulina, agente hipoglicêmico, agente imunorregulador, inibidor de aldose redutase, inibidor de 5-lipoxigenase, supressor de produção de lipìdios peroxidados, ativador de ppar, antagonista de leucotrienos, promotor de formação hidroxiadipocelular ou antagonista de cálcio, agente preventivo e/ou terapêutico, derivados de ácido carboxìlico, medicamento, composição farmacêutica, e, uso de um compostoInfo
- Publication number
- BR0009593A BR0009593A BR0009593-1A BR0009593A BR0009593A BR 0009593 A BR0009593 A BR 0009593A BR 0009593 A BR0009593 A BR 0009593A BR 0009593 A BR0009593 A BR 0009593A
- Authority
- BR
- Brazil
- Prior art keywords
- agent
- carboxylic acid
- therapeutic
- inhibitor
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
"AGENTE MELHORADOR DE RESISTêNCIA á INSULINA, AGENTE HIPOGLICêMICO, AGENTE IMUNORREGULADOR, INIBIDOR DE ALDOSE REDUTASE, INIBIDOR DE 5-LIPOXIGENASE, SUPRESSOR DE PRODUçãO DE LIPìDIOS PEROXIDADOS, ATIVADOR DE PPAR, ANTAGONISTA DE LEUCOTRIENOS, PROMOTOR DE FORMAçãO HIDROXIADIPOCELULAR OU ANTAGONISTA DE CáLCIO, AGENTE PREVENTIVO E/OU TERAPêUTICO, DERIVADOS DE áCIDO CARBOXìLICO, MEDICAMENTO, COMPOSIçãO FARMACêUTICA, E, USO DE UM COMPOSTO". Derivados de ácido carboxílico substituído em <244> de fórmula geral ( I ): [ em que R~ 1~, é um grupo alquila, etc., R~ 2~ é um átomo de hidrogênio, etc., R~ 3~ é um átomo de hidrogênio, etc., A é grupo = CH-, etc., B é um átomo de oxigênio, etc., W~ 1~ é um grupo C~ 1~-C~ 8~ alquileno, W~ 2~ é uma ligação simples ou um grupo C~ 1~-C~ 8~ alquileno, X é um átomo de hidrogênio, etc., Y é um átomo de oxigênio, etc., e Z~ 1~ é um grupo alcóxi, etc. ], ou sais farmacologicamente aceitáveis dos mesmos, ésteres farmacologicamente aceitáveis dos mesmos ou amidas farmacologicamente aceitáveis dos mesmos são úteis como agentes terapêuticos e/ou agentes preventivos para diabetes melito, insuficiência de tolerância à glucose, diabetes melito gestacional, ou análogos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9928699 | 1999-04-06 | ||
JP21514199 | 1999-07-29 | ||
PCT/JP2000/002215 WO2000059889A1 (en) | 1999-04-06 | 2000-04-06 | α-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0009593A true BR0009593A (pt) | 2002-06-18 |
Family
ID=26440432
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0009593-1A BR0009593A (pt) | 1999-04-06 | 2000-04-06 | Agente melhorador de resistência à insulina, agente hipoglicêmico, agente imunorregulador, inibidor de aldose redutase, inibidor de 5-lipoxigenase, supressor de produção de lipìdios peroxidados, ativador de ppar, antagonista de leucotrienos, promotor de formação hidroxiadipocelular ou antagonista de cálcio, agente preventivo e/ou terapêutico, derivados de ácido carboxìlico, medicamento, composição farmacêutica, e, uso de um composto |
Country Status (18)
Country | Link |
---|---|
US (2) | US6596751B2 (pt) |
EP (1) | EP1167357A4 (pt) |
KR (1) | KR20020060067A (pt) |
CN (1) | CN1208323C (pt) |
AU (1) | AU760163B2 (pt) |
BR (1) | BR0009593A (pt) |
CA (1) | CA2369871A1 (pt) |
CZ (1) | CZ20013593A3 (pt) |
HK (1) | HK1039939A1 (pt) |
HU (1) | HUP0200895A3 (pt) |
IL (1) | IL145732A0 (pt) |
MX (1) | MXPA01010109A (pt) |
NO (1) | NO20014849L (pt) |
NZ (1) | NZ514661A (pt) |
PL (1) | PL351898A1 (pt) |
RU (1) | RU2219172C2 (pt) |
TR (1) | TR200102908T2 (pt) |
WO (1) | WO2000059889A1 (pt) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1695716A2 (en) * | 2000-12-26 | 2006-08-30 | Sankyo Company, Limited | Medicinal compositions containing diuretics and insulin sensitizers |
WO2003002550A1 (en) * | 2001-06-28 | 2003-01-09 | Dr. Reddy's Research Foundation | Dioxalane derivatives and a process for their preparation |
WO2003010157A1 (en) * | 2001-07-23 | 2003-02-06 | Dr. Reddy's Research Foundation | Dioxane derivatives and a process for their preparation |
US7067530B2 (en) | 2001-07-30 | 2006-06-27 | Novo Nordisk A/S | Compounds, their preparation and use |
JP2004536152A (ja) * | 2001-07-30 | 2004-12-02 | ノボ ノルディスク アクティーゼルスカブ | 新規ビニルn−(2−ベンゾイルフェニル)−l−チロシン誘導体及び抗糖尿病剤等へのそれらの使用 |
WO2003011834A1 (en) * | 2001-07-30 | 2003-02-13 | Novo Nordisk A/S | Novel vinyl n-(2-benzoylphenyl)-l-tyrosine derivatives and their use as antidiabetics etc |
FR2829765A1 (fr) * | 2001-09-14 | 2003-03-21 | Lipha | Derives imidazolylalkoxylarylalcanoiques leurs applications en therapeutique |
GB0314079D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
SE0104334D0 (sv) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
GB0229931D0 (en) | 2002-12-21 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
AU2002347022A1 (en) * | 2001-12-20 | 2003-07-09 | Novo Nordisk A/S | Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten |
ES2292937T3 (es) * | 2002-02-21 | 2008-03-16 | Eli Lilly And Company | Moduladores para el receptor activado por el proliferador de peroxisomas. |
US8980952B2 (en) * | 2002-03-20 | 2015-03-17 | University Of Maryland, Baltimore | Methods for treating brain swelling with a compound that blocks a non-selective cation channel |
AU2003222020B2 (en) | 2002-03-20 | 2008-08-28 | University Of Maryland Baltimore | A non-selective cation channel in neural cells and methods for treating brain swelling |
TW200408628A (en) * | 2002-08-02 | 2004-06-01 | Sankyo Co | Resorcinol and its derivatives |
PL213095B1 (pl) * | 2002-08-08 | 2013-01-31 | Kissei Pharmaceutical | Pochodna pirazolu, kompozycja farmaceutyczna, srodek do leczenia lub hamowania choroby i zastosowanie pochodnej pirazolu |
ZA200501094B (en) * | 2002-08-08 | 2006-10-25 | Kissei Pharmaceutical | Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof |
AR041481A1 (es) * | 2002-10-07 | 2005-05-18 | Hoffmann La Roche | Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar |
AU2003296405A1 (en) | 2003-01-06 | 2004-08-10 | Eli Lilly And Company | Fused heterocyclic derivatives as ppar modulators |
CN1751037A (zh) | 2003-02-14 | 2006-03-22 | 伊莱利利公司 | 作为ppar调节剂的磺酰胺衍生物 |
WO2004100525A2 (en) * | 2003-05-05 | 2004-11-18 | Thomson Licensing S.A. | System and method for blocking television signal having multiple different content ratings |
GB0314129D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
GB0314136D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
ATE486606T1 (de) * | 2004-09-18 | 2010-11-15 | Univ Maryland | Therapeutische mittel zum targeting des ncca-atp- kanals und verwendungsverfahren dafür |
AU2005287090A1 (en) | 2004-09-18 | 2006-03-30 | Department Of Veterans Affairs | Therapeutic agents targeting the NCca-ATP channel and methods of use thereof |
TW200637856A (en) * | 2005-01-24 | 2006-11-01 | Sankyo Co | Process for producing thiazolidinedion compound and intermediate thereof |
KR100811100B1 (ko) * | 2006-09-27 | 2008-03-06 | 한국생명공학연구원 | 벤즈아졸 유도체를 유효성분으로 함유하는 대사성 질환예방 및 치료용 약학적 조성물 |
CA2674949A1 (en) | 2007-01-12 | 2008-07-24 | J. Marc Simard | Targeting ncca-atp channel for organ protection following ischemic episode |
US20100092469A1 (en) * | 2007-02-09 | 2010-04-15 | Simard J Marc | Antagonists of a non-selective cation channel in neural cells |
EP2139330B1 (en) * | 2007-03-23 | 2014-09-24 | The Board of Regents of The University of Texas System | Methods involving aldose reductase inhibitors |
BRPI0809643A2 (pt) * | 2007-04-05 | 2014-11-11 | Daiichi Sankyo Co Ltd | Derivados de heteroarila bicíclica fundida |
CA2691199C (en) | 2007-06-22 | 2017-09-12 | Marc J. Simard | Inhibitors of ncca-atp channels for therapy |
WO2010002075A1 (en) * | 2008-07-02 | 2010-01-07 | Pharmacostech Co., Ltd. | Methods for preparing amide derivatives |
RU2480463C1 (ru) | 2009-03-05 | 2013-04-27 | Дайити Санкио Компани, Лимитед | Пиридилокси производные, полезные в качестве активатора/модулятора гамма-рецептора, активируемого пролифератором пероксисом (ppar) гамма |
WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
CN102946882B (zh) * | 2010-02-02 | 2016-05-18 | 格斯有限公司 | 苯基丙氨酸衍生物及其作为非肽glp-1受体调节剂的用途 |
CN104744282A (zh) * | 2015-02-17 | 2015-07-01 | 南通恒盛精细化工有限公司 | 一种胰岛素增敏剂的制备工艺 |
WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4942245A (en) | 1987-04-20 | 1990-07-17 | Kyorin Pharmaceutical Co., Ltd. | Benzimidazole Derivatives |
CA2150550A1 (en) | 1992-12-01 | 1994-06-09 | Melissa S. Egbertson | Fibrinogen receptor antagonists |
WO1995032710A1 (en) | 1994-05-27 | 1995-12-07 | Merck & Co., Inc. | Compounds for inhibiting osteoclast-mediated bone resorption |
BR9508178A (pt) | 1994-06-29 | 1997-11-18 | Smithkline Beecham Corp | Antagonistas de receptor de vitronectina |
IL118474A (en) * | 1995-06-01 | 2001-08-08 | Sankyo Co | Benzimideol derivatives and pharmaceutical preparations containing them |
GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
DE19629817A1 (de) | 1996-07-24 | 1998-01-29 | Hoechst Ag | Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
WO1998031359A1 (en) | 1997-01-17 | 1998-07-23 | Merck & Co., Inc. | Integrin antagonists |
WO1999029640A2 (en) | 1997-12-05 | 1999-06-17 | Eisai Co., Ltd. | Compositions and methods for modulating the activity of fibroblast growth factor |
DE69828445D1 (de) * | 1998-04-23 | 2005-02-03 | Reddys Lab Ltd Dr | Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen |
TWI250160B (en) | 1999-07-06 | 2006-03-01 | Sankyo Co | Crystalline 1-methylcarbapenem compound |
-
2000
- 2000-04-06 TR TR2001/02908T patent/TR200102908T2/xx unknown
- 2000-04-06 BR BR0009593-1A patent/BR0009593A/pt not_active IP Right Cessation
- 2000-04-06 CA CA002369871A patent/CA2369871A1/en not_active Abandoned
- 2000-04-06 NZ NZ514661A patent/NZ514661A/xx unknown
- 2000-04-06 CN CNB008083274A patent/CN1208323C/zh not_active Expired - Fee Related
- 2000-04-06 MX MXPA01010109A patent/MXPA01010109A/es unknown
- 2000-04-06 CZ CZ20013593A patent/CZ20013593A3/cs unknown
- 2000-04-06 EP EP00915361A patent/EP1167357A4/en not_active Withdrawn
- 2000-04-06 WO PCT/JP2000/002215 patent/WO2000059889A1/ja not_active Application Discontinuation
- 2000-04-06 IL IL14573200A patent/IL145732A0/xx unknown
- 2000-04-06 HU HU0200895A patent/HUP0200895A3/hu unknown
- 2000-04-06 AU AU36707/00A patent/AU760163B2/en not_active Ceased
- 2000-04-06 RU RU2001127083/04A patent/RU2219172C2/ru not_active IP Right Cessation
- 2000-04-06 PL PL00351898A patent/PL351898A1/xx not_active Application Discontinuation
- 2000-04-06 KR KR1020017012729A patent/KR20020060067A/ko not_active Application Discontinuation
-
2001
- 2001-10-05 US US09/972,206 patent/US6596751B2/en not_active Expired - Fee Related
- 2001-10-05 NO NO20014849A patent/NO20014849L/no not_active Application Discontinuation
-
2002
- 2002-02-26 HK HK02101454.5A patent/HK1039939A1/zh unknown
-
2003
- 2003-02-28 US US10/376,942 patent/US20040002512A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
NZ514661A (en) | 2003-06-30 |
TR200102908T2 (tr) | 2002-04-22 |
EP1167357A1 (en) | 2002-01-02 |
US20040002512A1 (en) | 2004-01-01 |
HUP0200895A2 (hu) | 2002-11-28 |
AU3670700A (en) | 2000-10-23 |
CN1353694A (zh) | 2002-06-12 |
MXPA01010109A (es) | 2002-06-04 |
HUP0200895A3 (en) | 2002-12-28 |
NO20014849L (no) | 2001-11-27 |
AU760163B2 (en) | 2003-05-08 |
CN1208323C (zh) | 2005-06-29 |
CA2369871A1 (en) | 2000-10-12 |
PL351898A1 (en) | 2003-06-30 |
IL145732A0 (en) | 2002-07-25 |
WO2000059889A1 (en) | 2000-10-12 |
RU2219172C2 (ru) | 2003-12-20 |
US20030069294A1 (en) | 2003-04-10 |
US6596751B2 (en) | 2003-07-22 |
NO20014849D0 (no) | 2001-10-05 |
EP1167357A4 (en) | 2002-06-05 |
HK1039939A1 (zh) | 2002-05-17 |
KR20020060067A (ko) | 2002-07-16 |
CZ20013593A3 (cs) | 2002-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0009593A (pt) | Agente melhorador de resistência à insulina, agente hipoglicêmico, agente imunorregulador, inibidor de aldose redutase, inibidor de 5-lipoxigenase, supressor de produção de lipìdios peroxidados, ativador de ppar, antagonista de leucotrienos, promotor de formação hidroxiadipocelular ou antagonista de cálcio, agente preventivo e/ou terapêutico, derivados de ácido carboxìlico, medicamento, composição farmacêutica, e, uso de um composto | |
PE20040655A1 (es) | Nuevos derivados de glicosido de tiofeno, procedimientos para su preparacion y medicamentos que los contienen | |
RU2312106C2 (ru) | Замещенные 4-алкоксиоксазолпроизводные в качестве агонистов ppar | |
BRPI0507944A (pt) | composição farmacêutica | |
TW200420549A (en) | Thiazole derivatives | |
MXPA04001253A (es) | Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo. | |
CA2690841A1 (en) | Synthetic bile acid composition, method, and preparation | |
AU2001280438A1 (en) | Substituted heterocyclic amides | |
ES2523873T3 (es) | Administración de un inhibidor parcial de la oxidación de ácidos grasos, tal como ranolazina, para el tratamiento de la diabetes | |
IL145759A (en) | Amine derivatives and pharmaceutical compositions containing the same | |
BR9908706A (pt) | Derivado de benzofuril-alfa-pirona, composição farmacêutica, acentuador de metabolismo de lipìdeos, inibidor de biossìntese de triglicerìdeos, agente redutor de triglicerìdeos do sangue, agente elevador de hdl do sangue, agente profilático para a arteriosclerose, e, agente de tratamento para a arteriosclerose | |
WO2004046122A3 (en) | Benzoxazole, benzthiazole and benzimidazole acid derivatives and their use as heparanase inhibitors | |
HRP20041026A2 (en) | Polycyclic compounds as potent alpha2-adrenoceptor antagonists | |
SV2004001294A (es) | Derivados de acido acetico ref. lea 35699-sv | |
BR0314754A (pt) | Agente terapêutico ou profilático para a frequência urinária ou a incontinência urinária ou um seu sal de adição de ácido farmaceuticamente aceitável, método para terapia ou profilaxia para frequência urinária, urgência urinária ou incontinência urinária, uso de um derivado de morfina tendo um grupo heterocìclico contendo nitrogênio ou de um seu sal de adição de ácido farmaceuticamente aceitável, derivado de morfina ou um seu sal de adição de ácido farmaceuticamente aceitável, produto farmacêutico, e, composição farmacêutica | |
AR037521A1 (es) | Derivados de piperazina que tienen actividad antagonista del sst1, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de la depresion, ansiedad y padecimientos bipolares y una combinacion | |
US4940730A (en) | Angiogenesis enhancer | |
JPS6461465A (en) | Hydantoin derivative and medicine composition containing said derivative as active ingredient | |
CA2494601A1 (en) | N-substituted-1h-indol-5-propionic acid compounds as ppar agonists useful for the treatment of diabetes | |
RU2011108587A (ru) | Новые метилендиоксифенольные соединения и их применение для лечения заболеваний | |
BRPI0413500A (pt) | compostos, processos para a sua preparação, composição farmacêutica que compreende os mesmos, utilização de um composto, métodos para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade | |
HU9800970D0 (en) | Process for producing pharmaceutical compositions containing heptapeptide somatostatin derivatives of neurogene- and non-neurogene-antiflogistic and analgesic activity and peptidomimetica | |
AR053584A1 (es) | Compuesto de hidroxi ciclopentanona substituido su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende | |
PE20130241A1 (es) | Agente terapeutico de liberacion sostenida para la hipertension y la disfuncion renal | |
EP1174421A4 (en) | 3-AMIDINOBENZENESULFONAMIDE DERIVATIVES, MEDICAL PREPARATIONS CONTAINING IT AND INTERMEDIATE PRODUCTS IN THEIR PRODUCTION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A , 8A E 9A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 NA RPI2003 DE 26/05/2009. |